• HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
    • My account
    • Cart
  • CONTACT
Type and hit ENTER
  • HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
    • My account
    • Cart
  • CONTACT
GET CONNECTED
  • HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
    • My account
    • Cart
  • CONTACT
ProAxsis Limited appoints first distributor for DACH region
Share
Announcements, News

ProAxsis Limited appoints first distributor for DACH region

December 14, 2020
-
Posted by David Ribeiro

ProAxsis Limited (www.proaxsis.com), the Belfast-based diagnostics company specialising in the measurement of active proteases and other inflammatory biomarkers, today announces that it has appointed Hölzel Diagnostika as the first distributor of its portfolio of respiratory research assays in Europe.

Based in Cologne and founded in 1993, Hölzel Diagnostika specialises in the commercialisation of high-quality laboratory and research products in the DACH region countries of Germany, Austria and Switzerland. This partnership agreement enables them to add ProAxsis’ activity-based immunoassay kits for the quantification of the active forms of neutrophil elastase, proteinase 3 and cathepsin G to their extensive portfolio of more than six million products.

Speaking about the agreement, Dr David Ribeiro, CEO of ProAxsis, said: “Following close on the heels of our recent agreement with Diapharma for distribution rights in North America, we’re excited to finalise this agreement with Hölzel for another critically important geographical sales territory.  Hölzel has outstanding existing commercial relationships in place with more than 90% of all university and pharmaceutical company laboratories in the DACH region, providing access to our product portfolio for this key customer group.”

Christina Neumann, Product Manager at Hölzel Diagnostika, added: “We’re delighted to have gained access to the innovative ProteaseTag® technology of ProAxsis and look forward to providing our research laboratory customers in Germany, Austria and Switzerland with solutions for the specific quantification of these key protease biomarkers.”

Any enquiries concerning ProAxsis’ work with proteases and other inflammatory biomarkers can be directed to info@proaxsis.com. 

To learn more about Hölzel Diagnostika, please visit www.hoelzel-biotech.com.

ABOUT PROAXSIS

ProAxsis Limited is a commercial-stage diagnostics company, based in Northern Ireland, and with a rapidly growing global client list of pharmaceutical companies and academic laboratories. The company has developed activity-based immunoassays for the specific quantification of the active form of Neutrophil Elastase, Proteinase 3 and Cathepsin G, as potential biomarkers of lung infection and inflammation in chronic respiratory diseases such as Chronic Obstructive Pulmonary Disease (COPD), cystic fibrosis and bronchiectasis. 

This technology has been translated into a point-of-care test (NEATstik®), to enable ongoing monitoring of active NE levels.  Recently published data has shown that measuring active NE levels using NEATstik® enables identification of patients with airway bacterial infection and those patients at highest risk of suffering pulmonary exacerbations over the subsequent 12 months.

In addition to proteases, the company also has significant expertise in the measurement of other inflammatory biomarkers, including IL-6, IL-8 and TNF-alpha.

Aside from the provision of assays, ProAxsis is able to offer a sample analysis service at its purpose-built laboratory facility in Belfast, and is currently supporting a number of pharmaceutical company-sponsored Phase I, II and III clinical trials.

ProAxsis became a fully owned subsidiary of Netscientific plc in October 2020. 

ABOUT HÖLZEL DIAGNOSTIKA

Hölzel Diagnostika is your partner when it comes to high quality products for your laboratory and research. The company offers more than six million products from well-known and international manufacturers from over 20 countries.

Hölzel Diagnostika offers you an individual service, so that you can quickly and easily receive your required products, even if we have not listed them yet.

Additionally 90% of all DACH universities and pharmaceutical companies have negotiated individual conditions and discounts.

27 years as a Life Science Distributor on the market have given Hölzel Diagnostika a wealth of experience and expertise in various fields. Since their foundation, reliability, interest and commitment have been the key to Hölzel Diagnostika’s success.

December 14, 2020

Related News

Other posts that you should not miss.
Announcements, ProteaseTag®

ProAxsis technology highlighted in AJRCCM editorial

May 17, 2017
-
Posted by Webmaster

ProAxsis Ltd is delighted to observe that its ProteaseTag® Active Neutrophil Elastase Immunoassay is prominently featured in the …

Read More
May 17, 2017
Posted by Webmaster
News

ProAxsis assays selected for inclusion in major new ERS-funded study

September 20, 2018
-
Posted by David Ribeiro

ProAxsis Limited (www.proaxsis.com), the Belfast-based company focused on developing new assays for the measurement of active protease biomarkers …

Read More
September 20, 2018
Posted by David Ribeiro
Conferences, News

ProAxsis team to attend BIO 2016

June 2, 2016
-
Posted by Webmaster

ProAxsis will be attending the BIO 2016 conference, taking place at the Moscone Convention Center in San Francisco between …

Read More
June 2, 2016
Posted by Webmaster
NEXT POST →
ProAxsis Limited supported by Innovate UK to accelerate work on inflammatory biomarkers associated with COVID-19
Categories
  • Announcements
  • Conferences
  • NEATstik®
  • Neutrophil Elastase Immunoassay
  • News
  • ProteaseTag®
  • Trials
  • Video
GET CONNECTED
RECENT POSTS
  • ProAxsis Limited supported by Innovate UK to accelerate work on inflammatory biomarkers associated with COVID-19
    December 10, 2020

    ProAxsis (www.proaxsis.com), the Belfast-based respiratory diagnostics company, today announces that it has been …

  • ProAxsis Limited recognised as Gold Level Innovator by Innovate NI
    December 2, 2020

    ProAxsis (www.proaxsis.com), the Belfast-based protease diagnostics company, is delighted to announce that it …

  • ProAxsis Limited appoints distributor for key North America region
    November 19, 2020

    ProAxsis Limited (www.proaxsis.com), the Belfast-based diagnostics company specialising in the measurement of active …


ProAxsis Ltd
Unit 1B, Concourse Building 3,
Catalyst Inc,
Queen’s Road, Titanic Quarter,
Belfast,
BT3 9DT,
Northern Ireland

tel +44 (0)28 9073 0444
email info@proaxsis.com

RECENT NEWS
  • December 10, 2020
    ProAxsis Limited supported by Innovate UK to accelerate work on inflammatory biomarkers associated with COVID-19
  • December 2, 2020
    ProAxsis Limited recognised as Gold Level Innovator by Innovate NI
  • November 19, 2020
    ProAxsis Limited appoints distributor for key North America region
LATEST TWEETS
Twitter
ProAxsis
Follow Me
ProAxsis is delighted to have received this support from Innovate UK - https://t.co/toTxOz9KK6
44 days ago
- ProAxsis
RT @GRobinsonDUP: I’m delighted that @ProAxsis based in East Belfast have been successful in their application for an Innovate UK Grant, wh…
44 days ago
- ProAxsis
We are delighted to announce that as of today, we have appointed an exclusive distributor for our portfolio of prod… https://t.co/rmCmIugsLa
65 days ago
- ProAxsis
Due to our continued expansion, we wish to recruit an Administration Officer. This post can be full-time or part-ti… https://t.co/k3wKwVfOKy
85 days ago
- ProAxsis
Copyright © 2016-2018 - ProAxsis - All rights reserved. 
ProAxsis Limited appoints first distributor for DACH region | ProAxsis